National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

Denosumab May Help Prevent Bone Loss

Past Highlights
 
 
Results: 1 -10 of 22    Show     results per page
View Search Criteria | Help With Results
Title 
Phase sort descending
Protocol IDs 
 
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

   
Phase III, Phase II

   
06-2247
NCT00442533

 
 
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

   
Phase III

   
A6181111
NCT00428597

 
 
Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors

   
Phase III

   
CRAD001C2324
NCT00510068

 
 
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

   
Phase II, Phase I

   
UCSF-04458
NCT00227617

 
 
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

   
Phase II, Phase I

   
CTCT 06-11
NCT00493883

 
 
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

   
Phase II, Phase I

   
07-325
NCT00576680

 
 
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

   
Phase II

   
NCI-04-C-0273
NCI-6332, DELCATH-G990039, NCT00096083

 
 
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

   
Phase II

   
END0002
97273, END0002, NCT00398320, NCT00398320

 
 
Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer

   
Phase II

   
MDA-2006-0077
MDACC 2006-0077, 7650, NCT00454363

 
 
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

   
Phase II

   
MCC-14888
NCT00434109

 
      1 2 3   Next >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov